公开(公告)号：WO2009089462A1

公开(公告)日：2009-07-16

申请号：PCT/US2009/030617

申请日：2009-01-09

Applicant: ARRAY BIOPHARMA INC. ,  GENENTECH, INC. ,  BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  HENTEMANN, Martin F. ,  KALLAN, Nicholas C. ,  LIANG, Jun ,  MITCHELL, Ian S. ,  SCHLACHTER, Stephen T. ,  WALLACE, Eli M. ,  XU, Rui ,  TANG, Tony, P.

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  HENTEMANN, Martin F. ,  KALLAN, Nicholas C. ,  LIANG, Jun ,  MITCHELL, Ian S. ,  SCHLACHTER, Stephen T. ,  WALLACE, Eli M. ,  XU, Rui ,  TANG, Tony, P.

IPC: C07D239/70 ,  A61K31/517 ,  A61P35/00 ,  C07D401/04 ,  C07D401/10 ,  C07D409/04 ,  C07D417/04 ,  C07D487/04

CPC classification number: C07D401/10 ,  C07D211/08 ,  C07D211/46 ,  C07D239/70 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04 ,  C07D417/10 ,  C07D487/04

Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).

Abstract translation: 式I化合物可用于抑制AKT蛋白激酶。 公开了使用式I化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。 式（I）。

公开(公告)号：WO2009089454A1

公开(公告)日：2009-07-16

申请号：PCT/US2009/030603

申请日：2009-01-09

Applicant: ARRAY BIOPHARMA INC. ,  BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  FONG, Kin Chiu ,  HENTEMANN, Martin F. ,  MITCHELL, Ian S. ,  SAMMOND, Douglas McCord ,  TANG, Tony P. ,  WALLACE, Eli M. ,  XU, Rui

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  FONG, Kin Chiu ,  HENTEMANN, Martin F. ,  MITCHELL, Ian S. ,  SAMMOND, Douglas McCord ,  TANG, Tony P. ,  WALLACE, Eli M. ,  XU, Rui

IPC: C07D471/10 ,  C07D487/10 ,  A61K31/517 ,  A61K31/438 ,  A61P35/00

CPC classification number: C07D471/10 ,  C07D487/10

Abstract: The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

Abstract translation: 本发明提供式（I）化合物，其包括互变异构体，拆分的对映异构体，拆分的非对映体，溶剂合物，代谢物，盐和药学上可接受的前药。 还提供了使用本发明化合物作为Akt蛋白激酶抑制剂和治疗Akt介导的疾病例如过度增殖性疾病如癌症的方法。

公开(公告)号：EP2240483A1

公开(公告)日：2010-10-20

申请号：EP09700747.0

申请日：2009-01-09

Applicant: Array Biopharma, Inc. ,  Banka, Anna ,  Bencsik, Josef R. ,  Blake, James F. ,  Fong, Kin Chiu ,  Hentemann, Martin F. ,  Mitchell, Ian S. ,  Sammond, Douglas McCord ,  Tang, Tony P. ,  Wallace, Eli M. ,  Xu, Rui

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  FONG, Kin Chiu ,  HENTEMANN, Martin F. ,  MITCHELL, Ian S. ,  SAMMOND, Douglas McCord ,  TANG, Tony P. ,  WALLACE, Eli M. ,  XU, Rui

IPC: C07D471/10 ,  C07D487/10 ,  A61K31/517 ,  A61K31/438 ,  A61P35/00

CPC classification number: C07D471/10 ,  C07D487/10

Abstract: The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

公开(公告)号：EP2240483B1

公开(公告)日：2013-02-27

申请号：EP09700747.0

申请日：2009-01-09

Applicant: Array Biopharma, Inc. ,  Banka, Anna ,  Bencsik, Josef R. ,  Blake, James F. ,  Fong, Kin Chiu ,  Hentemann, Martin F. ,  Mitchell, Ian S. ,  Sammond, Douglas McCord ,  Tang, Tony P. ,  Wallace, Eli M. ,  Xu, Rui

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  FONG, Kin Chiu ,  HENTEMANN, Martin F. ,  MITCHELL, Ian S. ,  SAMMOND, Douglas McCord ,  TANG, Tony P. ,  WALLACE, Eli M. ,  XU, Rui ,  GRAHAM, James

IPC: C07D471/10 ,  C07D487/10 ,  A61K31/517 ,  A61K31/438 ,  A61P35/00

CPC classification number: C07D471/10 ,  C07D487/10

公开(公告)号：EP2250155B1

公开(公告)日：2013-07-03

申请号：EP09701043.3

申请日：2009-01-09

Applicant: Array Biopharma, Inc. ,  Genentech, Inc.

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  HENTEMANN, Martin F. ,  KALLAN, Nicholas C. ,  LIANG, Jun ,  MITCHELL, Ian S. ,  SCHLACHTER, Stephen T. ,  WALLACE, Eli M. ,  XU, Rui ,  TANG, Tony, P.

IPC: C07D239/70 ,  A61K31/517 ,  A61P35/00 ,  C07D401/04 ,  C07D401/10 ,  C07D409/04 ,  C07D417/04 ,  C07D487/04

CPC classification number: C07D401/10 ,  C07D211/08 ,  C07D211/46 ,  C07D239/70 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04 ,  C07D417/10 ,  C07D487/04

公开(公告)号：EP2240483B8

公开(公告)日：2013-04-03

申请号：EP09700747.0

申请日：2009-01-09

Applicant: Array Biopharma, Inc.

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  FONG, Kin Chiu ,  HENTEMANN, Martin F. ,  MITCHELL, Ian S. ,  SAMMOND, Douglas McCord ,  TANG, Tony P. ,  WALLACE, Eli M. ,  XU, Rui ,  GRAHAM, James

IPC: C07D471/10 ,  C07D487/10 ,  A61K31/517 ,  A61K31/438 ,  A61P35/00

CPC classification number: C07D471/10 ,  C07D487/10

公开(公告)号：EP2250155A1

公开(公告)日：2010-11-17

申请号：EP09701043.3

申请日：2009-01-09

Applicant: Array Biopharma, Inc. ,  Genentech, Inc.

Inventor： BANKA, Anna ,  BENCSIK, Josef R. ,  BLAKE, James F. ,  HENTEMANN, Martin F. ,  KALLAN, Nicholas C. ,  LIANG, Jun ,  MITCHELL, Ian S. ,  SCHLACHTER, Stephen T. ,  WALLACE, Eli M. ,  XU, Rui ,  TANG, Tony, P.

IPC: C07D239/70 ,  A61K31/517 ,  A61P35/00 ,  C07D401/04 ,  C07D401/10 ,  C07D409/04 ,  C07D417/04 ,  C07D487/04

CPC classification number: C07D401/10 ,  C07D211/08 ,  C07D211/46 ,  C07D239/70 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04 ,  C07D417/10 ,  C07D487/04

Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).